Vision & Mission

Combining cancer vaccines
and T-cell therapies

ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).

Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

About us

Latest News

  • Published On: June 15th, 2023

    Download the presse release

    Lyon, France – June 15, 2023 – ErVaccine Technologies, a French biotechnology company developing next-generation therapeutic vaccines and cellular immunotherapies in oncology, […]

  • Published On: February 23rd, 2023

    Download the press release

    Lyon, France – February 23, 2023 – ErVaccine Technologies, a French biotech company developing next-generation therapeutic vaccines and cellular immunotherapies in oncology, announced today the inaugural […]

  • Published On: January 5th, 2023
    • ErVaccine is developing a therapeutic vaccine and cell therapy technology potentially applicable to many types of cancers
    • First vaccine […]

Latest Publications & Abstracts

  • Categories: Publications & abstractsPublished On: March 1st, 2023
  • Categories: Publications & abstractsPublished On: June 28th, 2022
  • Categories: Publications & abstractsPublished On: June 16th, 2022
  • Categories: Publications & abstractsPublished On: January 27th, 2022